PLIVA d.d. engages in the discovery, development, production, and distribution of generic and niche pharmaceutical products in Europe. It offers pharmaceutical ingredients and intermediates, such as anti-infectives, cytostatics, diuretics, various API, nutraceuticals, and intermediates. The company also offers animal health products, feed additives, and disinfectants, Insecticides, rat control products. In addition, it provides generic pharmaceutical products, including biologicals, cytostatics, and other generics. It has an agreement with Mayne Pharma Limited for the development of biosimilar granulocyte-colony stimulating factor (G-CSF) for the European, South East Asian, Middle Eastern, and Asia Pacific markets. PLIVA d.d. was formerly known as Kastel d.d. The company was founded in 1921 and is headquartered in Zagreb, Croatia. As of October 24, 2006, PLIVA d.d. is a subsidiary of Barr Pharmaceuticals, Inc.